Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/7340
NUCLEOPLASMIC CALCIUM BUFFERING SENSITIZES HUMAN SQUAMOUS CELL CARCINOMA TO ANTICANCER THERAPY
Nuclear calcium buffering
X-rays irradiation
A431 cells
Head and neck tumor
Autor(es)
Andrade, Lídia Maria de
Geraldo, Jony Marques
Gonçalves, Osvaldo Xavier
Leite, Miguel T. T.
Catarina, Anderson M.
Guimarães, Melissa Monteiro
Leme, Adriana Franco Paes
Yokoo, Sami
Machado, Carlos Roberto
Rajão, Matheus Andrade
Carvalho, Sandhra Maria
Gomes, Dawidson Assis
Aguiar, Carla Jeane
Fagundes, Elaine Maria de Souza
Zani, Carlos Leomar
Resende, Rodrigo Ribeiro
Martins Filho, Olindo Assis
Leite, Maria de Fátima
Geraldo, Jony Marques
Gonçalves, Osvaldo Xavier
Leite, Miguel T. T.
Catarina, Anderson M.
Guimarães, Melissa Monteiro
Leme, Adriana Franco Paes
Yokoo, Sami
Machado, Carlos Roberto
Rajão, Matheus Andrade
Carvalho, Sandhra Maria
Gomes, Dawidson Assis
Aguiar, Carla Jeane
Fagundes, Elaine Maria de Souza
Zani, Carlos Leomar
Resende, Rodrigo Ribeiro
Martins Filho, Olindo Assis
Leite, Maria de Fátima
Afiliação
Fundação Oswaldo Cruz. Centro de Pesquisas René Rachou. Belo Horizonte, MG, Brazil
São Francisco Radiotherapy Institute. Belo Horizonte, MG, Brazil
São Francisco Radiotherapy Institute. Belo Horizonte, MG, Brazil
São Francisco Radiotherapy Institute. Belo Horizonte, MG, Brazil
São Francisco Radiotherapy Institute. Belo Horizonte, MG, Brazil
Federal University of Vales do Jequitinhonha and Mucurí. Diamantina,MG, Brazil
National Laboratory of Biosciences. Campinas, SP, Brazil
National Laboratory of Biosciences. Campinas, SP, Brazil
Federal University of Minas Gerais. Department of Biochemistry and Immunology. Belo Horizonte, MG, Brazil
Federal University of Minas Gerais. Department of Biochemistry and Immunology. Belo Horizonte, MG, Brazil
Federal University of Minas Gerais. School of Engineering. Belo Horizonte, MG, Brazil
Federal University of Minas Gerais. Department of Biochemistry and Immunology. Belo Horizonte, MG, Brazil
Federal University of Minas Gerais. Department of Physiology and Biophysics. Belo Horizonte, MG, Brazil
Federal University of Minas Gerais. Department of Physiology and Biophysics. Belo Horizonte, MG, Brazil
René Rachou Research Center. Belo Horizonte,MG, Brazil
Federal University of Minas Gerais. Department of Biochemistry and Immunology. Belo Horizonte, MG, Brazil
Fundação Oswaldo Cruz. René Rachou Research Center. Belo Horizonte, MG, Brazil
Federal University of Minas Gerais. Department of Physiology and Biophysics. Belo Horizonte, MG, Brazil/Howard Hughes Medical Institute. USA
São Francisco Radiotherapy Institute. Belo Horizonte, MG, Brazil
São Francisco Radiotherapy Institute. Belo Horizonte, MG, Brazil
São Francisco Radiotherapy Institute. Belo Horizonte, MG, Brazil
São Francisco Radiotherapy Institute. Belo Horizonte, MG, Brazil
Federal University of Vales do Jequitinhonha and Mucurí. Diamantina,MG, Brazil
National Laboratory of Biosciences. Campinas, SP, Brazil
National Laboratory of Biosciences. Campinas, SP, Brazil
Federal University of Minas Gerais. Department of Biochemistry and Immunology. Belo Horizonte, MG, Brazil
Federal University of Minas Gerais. Department of Biochemistry and Immunology. Belo Horizonte, MG, Brazil
Federal University of Minas Gerais. School of Engineering. Belo Horizonte, MG, Brazil
Federal University of Minas Gerais. Department of Biochemistry and Immunology. Belo Horizonte, MG, Brazil
Federal University of Minas Gerais. Department of Physiology and Biophysics. Belo Horizonte, MG, Brazil
Federal University of Minas Gerais. Department of Physiology and Biophysics. Belo Horizonte, MG, Brazil
René Rachou Research Center. Belo Horizonte,MG, Brazil
Federal University of Minas Gerais. Department of Biochemistry and Immunology. Belo Horizonte, MG, Brazil
Fundação Oswaldo Cruz. René Rachou Research Center. Belo Horizonte, MG, Brazil
Federal University of Minas Gerais. Department of Physiology and Biophysics. Belo Horizonte, MG, Brazil/Howard Hughes Medical Institute. USA
Resumo em Inglês
Background: Calcium (Ca2+) signaling within the nucleus is known to play a crucial role in cell proliferation.
The aim of this study was to investigate whether nuclear Ca2+ buffering could improve the antitumor effect of X-rays
therapy on Human Squamous Cell Carcinoma (HSCC).
Methods: For these purpose, we developed an experimental protocol that simulated clinical radiotherapy and
prevented bystander effects of irradiation. HSCC, A431 cell line, was submitted to 10Gy cumulative X-rays therapy
alone (XR Cd 10Gy) or in association with the strategy that selectively buffer nuclear Ca 2+ (Ca 2+ n) signaling.
Results: Upon Ca 2+ n buffering, A431 cell proliferation rate decreased significantly as compared to control. Cell
cycle analysis showed that association of Ca2+ n buffering with XR Cd 10Gy increased the percentage of A431 cells
at G 2 /M and did not increase nuclear/mitochondrial DNA damages. Nonetheless, Ca 2+ n buffering prevented the
increase of the radioresistance-related biomarker ADAM-17 expression and EGFR activation induced by irradiation.
Furthermore, the association therapy almost completely abolished cell survival fraction even using approximately
half of the X-rays cumulative dose
Conclusions: Nuclear Ca 2+ buffering sensitizes human squamous cell carcinoma to X - rays irradiation treatment.
Palavras-chave em inglês
Human squamous cell carcinomaNuclear calcium buffering
X-rays irradiation
A431 cells
Head and neck tumor
Compartilhar